🇺🇸 FDA
Pipeline program

Realgar-Indigo Naturalis Formulation Combined with Anlotinib

2025PHD008-001

Approved small_molecule active

Quick answer

Realgar-Indigo Naturalis Formulation Combined with Anlotinib for Platinum-resistant Ovarian Cancer (PROC) is a Approved program (small_molecule) at The First People's Hospital of Lianyungang with 1 ClinicalTrials.gov record(s).

Program details

Company
The First People's Hospital of Lianyungang
Indication
Platinum-resistant Ovarian Cancer (PROC)
Phase
Approved
Modality
small_molecule
Status
active

Clinical trials